BPC-157 and TB-500 are two of the most frequently studied peptides in tissue-repair research, and they are often discussed together. This overview summarizes what each compound is, why researchers examine them in combination, and what the literature does and does not establish. It is intended as a research primer, not as guidance for use.
BPC-157 in Brief
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a sequence found in gastric juice. In preclinical research models it has been studied for its effects on connective tissue, the gastrointestinal tract, and angiogenesis (the formation of new blood vessels). Much of the published work is in animal models. For a fuller treatment, see our BPC-157 research overview.
TB-500 in Brief
TB-500 is a synthetic peptide related to thymosin beta-4, a naturally occurring protein involved in cell migration and actin regulation. Research has examined its role in cell motility and tissue organization in laboratory models. More detail is available in our TB-500 research overview.
Why the Two Are Studied Together
The rationale often cited for examining BPC-157 and TB-500 in parallel is that they are described as acting through different mechanisms. BPC-157 is frequently associated in the literature with angiogenic and gastrointestinal pathways, while TB-500 is associated with actin regulation and cell migration. Because these pathways are distinct, researchers sometimes design studies to observe whether the two compounds produce complementary effects in the same model. It is important to note that rigorous, controlled data on the combination specifically is limited, and much of the discussion is extrapolated from single-compound studies.
What the Literature Does — and Does Not — Establish
The individual compounds each have a body of preclinical literature, largely in animal models. Well-controlled human clinical data are limited for both, and combination-specific studies are scarcer still. Researchers evaluating these peptides should treat claims about synergy with appropriate skepticism and rely on primary sources rather than anecdote. As with any research compound, identity and purity of the material used are prerequisites for interpretable results.
Material Quality Matters
Any comparison or combination study is only as reliable as the material behind it. Both BPC-157 and TB-500 offered by Greatest Peptides ship with a batch-specific Certificate of Analysis documenting HPLC purity and LC-MS identity for the exact lot, so the compound in the vial matches the label. Browse both in the catalog.
For laboratory and research use only. Not for human or animal consumption. This article summarizes published research and is not a recommendation for use.
The short version
The article above treats the pairing as a research question. This expansion treats it as an experimental-design problem, which is where most of the difficulty actually sits. Two compounds applied together produce one observation, and one observation cannot be divided between two causes. Saying anything about a pair therefore requires a structure of comparisons that almost none of the material circulating about these two compounds contains: arms for each compound alone, an arm for the pair, and a vehicle arm, all run in the same model at the same time. Without that structure there is no interaction to measure, because interaction is defined only against the single-compound arms. The sections below set out what a factorial comparison can and cannot attribute, what the words additivity, synergy and antagonism mean when used precisely, how the physical format of a two-compound preparation changes what is confounded, what analytical evidence a two-component vial needs, and how to tell a mechanistic rationale apart from a demonstrated combined effect.
What an attribution claim actually requires
An observation belongs to whatever varied between the conditions that produced it. That single sentence governs everything else here, and it is the reason a two-compound experiment is harder to interpret than a one-compound experiment by more than a factor of two.
Consider the simplest version. A model is run with a preparation containing both compounds, something is measured, and the measurement is written down. There is no comparison, so there is nothing to attribute the measurement to; it is a description of that model under that condition and nothing more. Adding a vehicle arm improves this, but only to a specific and limited degree. Now the preparation as a whole can be compared against no compound at all, and a difference, if one appears, belongs to the preparation. It does not belong to either compound, because neither compound was ever varied on its own. Both were present or both were absent, so the two are perfectly confounded with each other and with the act of applying the preparation.
The structure that breaks the confound is a crossed, or factorial, design. Each compound is treated as a factor with two levels, present and absent, and the four resulting cells are all run: neither compound, the first alone, the second alone, and both. The vehicle cell is not a courtesy, it anchors the other three. From those four cells, three contrasts can be estimated. The main effect of the first compound is what changes when it is added, averaged across the presence and absence of the second. The main effect of the second is the mirror image. The interaction is what is left over: the extent to which the effect of one depends on whether the other is there. Only that third quantity has anything to do with the pair as a pair.
Two practical points follow. First, an experiment that compares the pair against one of the singles, without the other single, can say what adding the second compound did in the presence of the first, and cannot say anything about the second compound on its own or about the interaction. That is a common and genuinely useful design, but it is often written up as though it were the factorial. Second, interaction contrasts are estimated less precisely than main effects from the same data, because the interaction is a difference of differences and the variances add. A widely repeated rule of thumb in experimental design holds that detecting an interaction of a given magnitude needs roughly four times the group size required to detect a main effect of the same magnitude. Small exploratory work is therefore usually powered to detect main effects and not powered to detect the interaction it is being read for.
What each design can and cannot attribute
| Design | Arms present | Can attribute | Cannot attribute |
|---|---|---|---|
| Combination only | The pair, nothing else | Nothing; no comparison exists in the data | Any statement about either compound or about the pair |
| Combination versus vehicle | The pair, vehicle | That the preparation as a whole differed from vehicle | Which compound the difference belongs to, or whether both contributed |
| Combination versus one single | The pair, one compound alone, vehicle | What adding the second compound did in the presence of the first | The second compound on its own, and the interaction contrast |
| Full factorial at one level each | Each alone, the pair, vehicle | Both main effects and one interaction contrast | How that interaction behaves at other concentrations or ratios |
| Factorial across a concentration grid | Several levels of each, crossed, plus vehicle | A surface against which an additivity reference can be fitted | Anything about ratios and levels that were not run |
| Two combined preparations compared | The pair at two different ratios | Which of the two ratios differed from the other | Whether either compound contributed anything at all |
Reading down the last column is the fastest way to audit a claim. If someone states that two compounds work better together, find the arms. If the single-compound arms are absent, the statement is not weakly supported, it is undefined: the quantity being claimed was never estimated. That distinction is worth keeping sharp, because a weakly supported claim invites more data of the same kind, while an undefined one invites a different experiment entirely.
Note also that the table says nothing about how many replicates each arm contained. That is deliberate. Replication governs how precisely a contrast is estimated, but no amount of replication creates a contrast the arms do not define. A design in the top two rows does not improve with larger group sizes; it stays silent about exactly the same things, more precisely.
Additivity, synergy and antagonism as defined quantities
The word synergy has a technical meaning and a conversational one, and the two have drifted far enough apart that the same sentence can be rigorous or empty depending on who wrote it. In the technical sense, synergy is not a description of two things being useful at once. It is a statement that a combined effect exceeds what a stated reference model predicts from the individual effects. The reference model is not optional and it is not implied. Without one, the sentence has no truth conditions, because there is no prediction for the observation to exceed.
Several reference models exist and they do not agree with one another. Highest single agent is the least demanding: the combination is called more than additive if it exceeds the better of the two singles. Bliss independence assumes the two compounds act through independent routes and multiplies their fractional non-effects, which is appropriate when independence is plausible and misleading when the two share a route. Loewe additivity assumes the two behave as dilutions of one another and works in units of relative potency, which requires a concentration-response relationship for each compound alone. These models can classify the same data differently, which is why a serious combination analysis names its reference model before reporting a result rather than after.
Every one of those models needs the single-compound arms. Bliss independence needs each compound's fractional effect measured alone. Loewe additivity needs a full concentration-response curve for each compound alone in the same model, on the same readout, in the same run. This is the point where most informal synergy claims about this particular pair fail: not at the statistics, but at the inputs. The curves that the model requires were never generated, so the model was never applied, and the word is being used as an adjective.
Antagonism is the mirror image and carries the same requirement. A combined effect that falls below the reference prediction is antagonistic with respect to that reference, and only with respect to that reference. Potentiation is a narrower term, usually reserved for the case where one compound has little or no effect alone but shifts the concentration-response curve of the other, and demonstrating it therefore requires showing the inactive-alone arm explicitly.
For BPC-157 and TB-500 specifically, the honest description of the published record is that the inputs a formal additivity analysis needs are not there in any consolidated form. What circulates instead is a mechanistic story about two different routes of action, which is a hypothesis about why an interaction might be worth testing, not a measurement of one. Nobody has to be accused of anything for that to be true; it is simply what the shape of the available literature allows.
Interaction vocabulary and what each term requires
| Term | What it asserts formally | What has to exist for the claim to mean anything |
|---|---|---|
| Additive | The combined effect matches the reference prediction | A named reference model and the single-compound effects it consumes |
| Synergistic | The combined effect exceeds the reference prediction | The same, plus a stated criterion for how far above counts |
| Antagonistic | The combined effect falls below the reference prediction | The same inputs; the direction of the deviation is the only difference |
| Potentiating | One compound shifts the concentration-response curve of the other | A curve for the second compound with and without a fixed level of the first |
| Independent | Neither compound changes what the other does | The interaction contrast estimated and found near zero, with its precision reported |
| Complementary | No formal content; a claim about mechanism, not about effect | Nothing measurable; it is a rationale, and should be written as one |
The last row is the one to watch for in circulating material. Complementary and synergistic are frequently used as if interchangeable, and they sit on opposite sides of the line that separates a reason to run an experiment from a result of one. A rationale describes why two things might interact. A reference model plus four arms describes whether they did. Substituting the first for the second is the single most common error in writing about this pair.
The corollary is that an interaction claim is always bounded by the conditions that produced it. A departure from additivity observed at one ratio, on one readout, in one model, is a statement about that ratio, that readout and that model. It does not generalize to other proportions of the same two compounds, because the interaction is a property of the combination as configured rather than of the two molecules in the abstract.
Preparation format decides what is confounded
Before any of the design above can be run, someone has to decide how the two compounds physically exist during the experiment, and that decision quietly determines which comparisons remain possible. It is easy to treat this as a logistics question. It is not; it is part of the design.
A co-lyophilized vial containing both compounds is the most restrictive format. Whatever ratio was established at fill is the only ratio available, because the two cannot be separated afterward by any bench operation short of a preparative separation. Every aliquot moves both components together in lockstep, so varying the amount applied traces a single fixed-proportion path rather than a grid. There is no way to build the single-compound arms from that vial, so the factorial cannot be completed with it alone; the singles have to be obtained separately, which reintroduces a difference between conditions, since the singles now come from different containers and different lots than the combined arm. The sharper version of the problem is that any experiment run only from a co-formulated vial has permanently lost the individual contributions. No later analysis recovers them, because the information was never in the data.
Two separate vials reconstituted separately and combined at the bench is more flexible and carries its own confounds. The ratio becomes a variable the experimenter sets, which is what a grid requires, but now the combined condition involves an extra mixing step, a possible difference in final diluent volume, and a shared vessel in which the two solutions sit together for some period before being applied. If the single-compound arms do not receive the same mixing step and the same final volume, the vehicle composition itself differs between arms, and that difference is confounded with the presence of the second compound. Matching the vehicle across all four cells is the fix, and it is routinely skipped.
Applying the two compounds as separate additions rather than a premixed solution avoids the shared-vessel question but introduces order and interval as new variables. Which went in first, and how long apart, are then part of the condition being tested, and a single arm cannot separate an interaction between compounds from an effect of sequence.
There is also a documentation confound that has nothing to do with chemistry. If the combined arm uses a commercially blended vial whose component amounts rest on the fill record rather than on measurement, then the nominal amounts in that arm carry an uncertainty the single-compound arms do not. The general arithmetic of component amounts in a blended vial is covered in the blends guide linked below; the design point here is narrower, which is that an unverified ratio makes the combined arm's position on any concentration axis approximate while the single arms remain exact.
How the physical format changes what the experiment can separate
| Preparation format | What is held constant | What becomes confounded |
|---|---|---|
| Co-lyophilized single vial | The ratio, exactly as filled, across every aliquot | The two components permanently; no arm within that vial varies one alone |
| Two vials, premixed at the bench | Component identity and lot, each verifiable alone | Mixing step, final diluent volume and shared-vessel contact time, unless matched in every arm |
| Two vials, applied as separate additions | Each solution stays in its own vessel until application | Order and interval; sequence effects cannot be separated from interaction |
| Combined arm from a blend, singles from own vials | Nothing across arms except the model itself | Lot, container, vehicle composition and nominal amounts all differ alongside the factor of interest |
| Two vials, all four arms volume-matched | Vehicle composition, final volume and handling across all cells | Little beyond the compounds themselves, which is the point of the format |
The last row is the only format in which the factorial is clean, and it is the most work. That is the trade. A co-formulated vial is convenient at the bench and expensive at the point of interpretation, because the convenience is purchased by permanently merging the two variables the experiment is supposed to distinguish. When the pair itself is the object of study, for instance in compatibility or stability work on a co-formulated preparation, that merging is not a flaw at all. When the aim is attribution, it is fatal.
Analytical evidence a two-component vial has to carry
A two-component preparation cannot be described by a single purity percentage, and the reason is structural rather than a matter of the number being slightly wrong. Area-percent arithmetic assumes one intended peak and treats everything else as an impurity. With two intended peaks, the routine has no way to decide which one it is describing. What a two-component vial needs instead is a per-component set of evidence: identity for each, content for each, and a demonstrated separation between them.
Identity is the easier half, and it is genuinely per-component. Each compound has its own theoretical mass computed from its own sequence, and each needs an observed mass compared against that theoretical value within a stated tolerance. A certificate that confirms one mass and stays silent about the other has confirmed one component. A certificate that reports a single mass for a two-component vial has reported something that cannot be correct for both.
The awkward part is that these two compounds are not similar in size, and that difference propagates through the whole analysis. A short peptide of a dozen or so residues and a fragment several times longer behave differently on a reversed-phase column, differently in an electrospray source, and differently in how their mass spectra deconvolute. The longer species distributes its signal across a wider set of charge states, so its apparent intensity is spread thinner than a naive comparison against the shorter species would suggest. Peak intensity in a mass spectrum was never a reliable proxy for abundance within one compound, and across two compounds of very different size it is worse than unreliable.
Chromatography carries the same asymmetry. A gradient tuned to give a short, relatively polar peptide adequate retention may push a longer, more hydrophobic species late into the run or leave it poorly shaped, while a gradient suited to the longer species may leave the shorter one near the solvent front where integration is least trustworthy. A method that resolves both well is a method that was developed for the mixture, not one borrowed from either single. The document that demonstrates this is a chromatogram of the mixture with both component peaks identified by retention time, alongside chromatograms of each single run under the identical method so the assignments can be checked.
Content is the part most often missing. Knowing that both compounds are present and correctly identified says nothing about how much of each is there, and the ratio is exactly what the experiment's concentration axis depends on. Quantifying each component requires a reference standard for that component and a response factor determined for it, because two peptides do not give the same detector response per unit mass at the same wavelength. Without that, any ratio read directly off peak areas is systematically skewed in a direction that cannot be signed without knowing both response factors.
Per-component evidence for a two-component preparation
| Question about the vial | Why one figure or one method struggles | What answers it |
|---|---|---|
| Is the shorter component the named compound? | A single reported mass cannot match two different molecules | Its own observed versus theoretical mass, with a stated tolerance |
| Is the longer component the named compound? | Its charge-state envelope differs from the shorter one and needs its own deconvolution | A separate identity confirmation, reported independently |
| How much of each is present? | Area percent is an internal ratio, not a mass ratio across different compounds | Quantitation of each against its own reference standard |
| Is the stated ratio correct? | Unequal detector response per unit mass skews any area-based ratio | Response factors determined for each component at the monitored wavelength |
| Do the two components resolve? | One peak integrates as one component regardless of what is inside it | A mixture chromatogram plus each single run under the identical method |
| Which component does an impurity belong to? | The software cannot assign minor peaks to a parent in a mixture | Single-component impurity profiles run first, then matched by retention time |
The practical test for a two-component certificate is whether the document ever distinguishes its two components anywhere. Two retention times, two masses, two content figures and one method that demonstrably separates them is a description of the material. One percentage and one mass is a description of a calculation that assumed a single analyte. Neither compound in this pair is difficult to characterize alone; the difficulty is entirely a consequence of putting them in one container.
It is worth being explicit that this is an analytical problem and not a quality problem. A well made two-component vial and a poorly made one produce the same single percentage on a certificate written for a single analyte, which is why that figure cannot be used to tell them apart. The evidence has to be structured per component before it can distinguish anything.
Telling a mechanistic rationale apart from a measured effect
The pairing narrative is durable for a reason worth understanding rather than dismissing. It has the structure of a good hypothesis. Two compounds are described in the literature as acting through routes that are not obviously the same, both appear in overlapping kinds of preclinical model, and neither description contradicts the other. That is exactly the pattern that makes a combination worth testing. It is also, and this is the part that gets lost, a statement assembled entirely from single-compound work.
The logical move being made is that if two compounds act through different routes, their combined effect should be at least additive. That inference has an unstated premise, which is that the two routes are genuinely independent in the system being measured. Independence at the level of a described mechanism does not imply independence at the level of a readout. Two routes can converge on a shared downstream limit, in which case the combined effect saturates and looks sub-additive. They can compete for a shared resource. One can alter the local environment in a way that changes how the other behaves. All of these are ordinary outcomes, none of them is visible from the mechanistic descriptions, and distinguishing between them is precisely what the interaction contrast is for.
There is also an origin problem with the mechanistic descriptions themselves. They were derived independently, in different literatures, by different groups, usually in different model systems, and each description was constructed to explain that compound's own observations. Placing two such descriptions side by side produces a picture that looks coherent because nothing in it was ever tested against the other. Coherence achieved by never running the comparison is not evidence of anything. The two individual guides linked below go into what each of those single-compound literatures actually consists of.
A reader can apply a short test to any statement encountered about this pair. Ask what was measured, in what model, against which comparison arms. If the answer names a mechanism rather than a measurement, the statement is a rationale. If it names a measurement but no comparison arms, it is an observation without attribution. If it names arms but only the combined one and a vehicle, it is a statement about a preparation, not about two compounds. Only when both single arms appear does the sentence have room to be about the pair. Nothing about this test requires accusing anyone of dishonesty; most of the material in circulation is repeating a rationale it received as a conclusion, and the error is one of transmission rather than of intent.
Reading a statement about the pair back to its evidence
| Form of the statement | What it actually rests on | What it can legitimately support |
|---|---|---|
| The two act through different routes | Two separate single-compound literatures placed side by side | A reason to design a combination experiment |
| Their routes are complementary | The same, plus an assumption of independence at the readout | The same reason, stated less carefully |
| Both appear in similar preclinical models | Overlap in the kind of model chosen, not in results | That a shared model exists in which both could be run |
| The combined preparation differed from vehicle | One combined arm and a vehicle arm | A statement about that preparation, with no split between components |
| The combination exceeded both singles | Three arms plus vehicle, one concentration | A highest-single-agent comparison at that one point |
| The interaction departed from an additivity reference | A concentration grid plus a named reference model | A quantitative interaction claim, bounded by the ratios tested |
Rows one through three are rationales, row four is an observation, and only rows five and six contain anything about the pair as a pair. Most of what is written about these two compounds together lives in the first three rows while being phrased in the language of the last two. Sorting a claim into its row takes about a minute and settles most arguments about what the record supports.
The test also works in the other direction, which is its more useful application. Someone planning work on the pair can read the table upward from the bottom and see what the aimed-for sentence would cost: which arms have to exist, at how many levels, and which reference model has to be chosen in advance. That is a cheaper conversation to have before the experiment than after it.
What a defensible combination record documents
The record for a combination experiment is not the single-compound record run twice. It has to support statements about a pair, and pair statements depend on facts about each component being recorded in a way that lets the two be compared to each other and to the combined condition. The organizing principle is that anything which differs between arms for a reason other than the compounds themselves has to be written down, because a reader working out what an observation means will need to rule those differences out.
Per component, the record starts with identity and lot. Each compound needs its own lot number, its own identity confirmation, and its own content basis, and those have to be traceable to the specific containers used in that experiment rather than to the product generally. When the combined arm and the single arms draw from different containers, both sets of lot numbers belong in the record, because a difference between arms could belong to the lots rather than to the combination.
Next comes the amount basis. A nominal amount printed on a container is a starting point, not a measurement, and where net peptide content is known the record should state whether the concentration used was computed on gross weight or on peptide content. The two are different numbers and the difference is not small. If the combined arm comes from a preparation where each component's amount rests on a fill record rather than on an assay, that fact belongs in the record explicitly, since it means the two axes of the design are not known to equal precision.
Then the arms themselves. The record should state which cells were run, how many independent replicates each contained, whether the vehicle composition and final volume were matched across all cells, and whether the arms were run concurrently or at different times. Concurrency matters more than it sounds: single arms run last month and a combined arm run this week are separated by everything that changed in between.
Finally the analysis plan. Which reference model for additivity was chosen, and whether it was chosen before the data were seen, determines whether an interaction claim is a test or a description. The interaction contrast should be reported with its precision, not only as a verdict, and a null interaction with wide uncertainty should be written up as uninformative rather than as evidence of independence. A record built this way supports a modest, defensible sentence about the pair. A record missing these items can still support a sentence about each compound separately, which is usually the more honest place to stop.
Record items a combination write-up needs, per component and per arm
| Record item | What is captured for each component | Why the pair statement depends on it |
|---|---|---|
| Lot and identity | Lot number and its own identity confirmation, per container used | A difference between arms could belong to a lot rather than to the combination |
| Content basis | Whether concentration was computed on gross weight or peptide content | The two bases differ, and mixing them across arms shifts the axis silently |
| Nominal versus assayed amount | Whether each component amount rests on a fill record or a measurement | An unverified ratio makes the combined arm approximate while singles stay exact |
| Preparation route | Vial format, mixing step, order and any interval between additions | Format and sequence are variables; unrecorded, they masquerade as interaction |
| Arms run and replication | Which cells existed, replicate counts, concurrency of the runs | The interaction contrast is undefined without both single arms in the same run |
| Vehicle matching | Final volume and diluent composition in every cell, including vehicle | Unmatched vehicle is confounded with the presence of the second compound |
| Analysis plan | The reference model chosen, and when it was chosen | A model selected after the data are seen converts a test into a description |
Nothing in that table is exotic and none of it requires extra instrumentation. It is mostly writing down decisions that were made anyway, at the time they were made, rather than reconstructing them later. The payoff is narrow and real: a record like this lets someone else determine which of the six rows in the previous section a given sentence belongs to, which is the whole question this guide has been circling.
The reverse case is worth naming too. A record that cannot support a pair statement is not a failed record. It is a complete record of two single-compound observations, which is a perfectly respectable thing to have produced, and writing it up as that is more useful to the next reader than a combination claim the arms were never built to carry.
Questions this guide gets asked
Why is a combined arm compared against vehicle not enough?
Because both compounds were present or both were absent, and nothing in between. The two are perfectly confounded with one another, so a difference from vehicle belongs to the preparation as a whole and cannot be divided. It could be driven entirely by one compound, by both roughly equally, or by an interaction, and the data contain no information that separates those possibilities. The comparison is not weak evidence about the individual compounds; it is no evidence about them at all, because the quantity that would describe them was never varied. To say anything about a component, that component has to appear in an arm where the other one is absent.
Can the two single-compound arms be borrowed from earlier experiments?
Only with heavy caveats, and it changes what can be claimed. An interaction contrast is a difference of differences, and it assumes the compared cells were run under the same conditions. Arms run months apart differ in passage number, reagent lots, operator, ambient conditions and any number of unrecorded details, and all of those load onto the contrast alongside the compounds. Historical single-compound arms can be useful as context, for checking that the current runs look broadly consistent with earlier ones. They cannot serve as the reference cells for a formal interaction estimate. If the interaction is the question, the four cells belong in one run.
Does a shared research context make two compounds a natural pair?
It makes them a plausible pair to test, which is a different and much weaker claim. Grouping compounds by the kind of model they have appeared in is an organizing principle based on where researchers happened to look, not on a shared or complementary molecular target. Two compounds studied in overlapping model systems may act on the same limiting step, in which case combining them gains little, or on steps that interfere with one another. The literature overlap predicts neither outcome. It predicts only that a shared model exists in which both could reasonably be run, which is a starting condition for an experiment rather than a preview of its result.
Is a fixed-ratio combined preparation ever the right material?
Yes, when the preparation itself is the object of study. Compatibility work asking whether two compounds can coexist in one container without one degrading the other requires them to be in one container. Stability work on a co-formulated preparation is the same case. Method development for a per-component assay needs a genuine mixture to develop against. And a first-pass screen explicitly asking whether a combination is worth decomposing into arms can reasonably start with the combined preparation, provided the follow-up arms are planned rather than hoped for. The distinction is between choosing a mixture because the mixture is the question and choosing one because it was what was available.
What does it mean when an interaction estimate comes out near zero?
It depends entirely on the precision of that estimate, which is why the estimate should be reported with its uncertainty rather than as a verdict. A near-zero interaction with a narrow interval is informative: it says that over the conditions tested, the effect of one compound did not depend much on the presence of the other. A near-zero interaction with a wide interval says the experiment could not distinguish a substantial interaction from none, and it should be written up as uninformative. Since interaction contrasts are estimated less precisely than main effects from the same data, the second case is far more common than the first in small exploratory work.
Why do two published combination analyses reach opposite conclusions?
Most often because they used different reference models for additivity. Highest single agent, Bliss independence and Loewe additivity make different assumptions and can classify identical data differently, so a result labeled synergistic under one can be additive or even sub-additive under another. Differences in the readout, in the concentration range covered, and in the ratio tested contribute as well, since an interaction present at one ratio may be absent at another. The first thing to check when two analyses disagree is whether each one names its reference model. An analysis that does not name one has not applied a model, and its conclusion is a description rather than a test.
How should a write-up phrase a result when only the combined arm was run?
By describing the preparation rather than the compounds. A sentence of the form that a preparation containing both compounds, at stated amounts, differed from vehicle on a stated readout in a stated model is accurate and defensible. A sentence attributing the difference to either compound, or describing the two as acting together, goes beyond what the arms support. It is also worth stating plainly in the limitations that the design cannot attribute the observation to a component, since a reader who has to work that out from the methods section will reasonably wonder why it was not said. Understating a result costs nothing that matters.
Where to read next
- BPC-157: a research overview what the single-compound literature on this component consists of
- TB-500 and thymosin beta-4: a research overview fragment versus parent protein, and auditing the citations
- Research peptide blends explained the component mass arithmetic a blended vial requires
- Reading an HPLC chromatogram: purity by area how an area percent is produced, and why one figure cannot cover two analytes
- BPC-157 / GHK-Cu / TB-500 blend a co-formulated multi-component listing, documented as one
- Third-party lab testing and COAs
All materials referenced here are supplied strictly for laboratory research use. They are not drugs, foods, cosmetics, or medical devices, and they are not for human or veterinary use, diagnostic use, or any form of consumption. Nothing in this guide describes an outcome in a person or recommends combining any compounds outside a controlled research setting. The design and analysis points above are general descriptions of experimental practice and are not a substitute for a qualified statistician reviewing a specific study plan.